ATS 2024 Final Program

Click on the session title to view the speakers

236

TUESDAY • MAY 21

108 Lung Immune Cell Inflammasome Modulation to Volcanic Ash and Ash-derived Nontuberculous Mycobacteria 109 Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease 110 Fully Automatic Analysis of Bronchus-artery Dimensions and Ratios of 625 Chest CTS of Bronchiectasis Patients Participating in the Embarc Registry 111 A Clinical Study of Longitudinal Changes in Radiographic Findings in Pulmonary Mycobacterium Avium Complex Diseases 112 Characterization and Evaluation of Gene Expression Profile for Nontuberculous Mycobacterial Pulmonary Disease 113 Clinical Significance of Cavity Obliteration Following Treatment in Patients With Mycobacterium Avium Complex Pulmonary Disease 114 Progression and Its Predictors in Patents With NTM Pulmonary Disease: 2nd Analysis of a Prospective Cohort Study 115 Lung-on-a-Chip Platforms for Nontuberculous Mycobacterial Pulmonary Disease: A Comparative Inspection of Patient-derived Epithelial Configurations C28 MORE THAN MEET THE EYE: NOVEL INSIGHTS IN IPF PATHOGENESIS 9:15 a.m. - 11:15 a.m. San Diego Convention Center Room 30C-E (Upper Level) Poster Viewing 9:15-10:00 Discussion 10:00-11:15 701 Profibrotic Role of GPR87 in Pulmonary Fibrosis 702 Piezo2 Is an Important Mechano-receptor in Pulmonary Fibrosis 703 A Novel Transgenic Mouse Model Allowing for the Inducible Lung-specific Activation of the p38 a Mitogen-activated Protein Kinase BASIC • TRANSLATIONAL POSTER DISCUSSION SESSION

704 Epithelial Xbp1s Expression Leads to Distal Lung MUC5B Hyperproduction and Progression of Pulmonary Fibrosis Following Injury 705 The Role of Hedgehog-Interaction Protein (HHIP) in Pulmonary Fibrosis 706 Deletion of Epithelial Membrane Protein 2 Protects From Lung Fibrosis 707 Chemerin: A Novel Player in Pulmonary Fibrosis 708 Lung-targeted Delivery of Nrf2 Activator Attenuates the Development of Age-associated Lung Fibrosis 709 CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-ß Signaling 710 Collagen Prolyl-3-hydroxylase 1 Controls Collagen Quality and Extracellular Matrix Deposition 711 Inflammatory and Pro-fibrotic Signals Sequentially Drive Pathologic Differentiation of Fibroblasts in Pulmonary Fibrosis 712 Contribution of Sex Chromosomes to the Development of Pulmonary Fibrosis 713 Cholesterol Accumulation in Alveolar Macrophages Drives Pulmonary Fibrosis 714 PLVAP Targeting IPF and Non-IPF-PF Drives Pulmonary Fibrosis 715 Aberrant Alveolar Epithelial Cells Alter the Alveolar Mesenchyme to Promote Fibrosis in a Clinical Sftpc Mutation Model of Lung Fibrosis 716 Deficiency of DSP, An IPF Susceptibility Gene, Promotes Pulmonary Fibrosis 717 Lysosomal Phospholipase A2 Reduces Lipid Accumulation and Modulates Macrophages Profibrotic Phenotype in Lung Fibrosis 718 In Vitro Culture of Primary Human Lung Fibroblasts Induces Collagen Expression and Promotes the Expansion of CTHRC1-positive Cells 719 The Role of Endothelial Mechanotransduction in Pulmonary Fibrosis 720 Matrix Stiffness-derived Mechanosignaling Regulates SPP1 Expression in Macrophages 721 Estrogen Receptor Alpha Signaling Potentiates Fibrogenic Responses to Lung Injury 722 Alveolar Epithelial Mitochondrial Impairments in Pulmonary Fibrosis: The Role of AMPK Signaling

ATS 2024 Conference Program • San Diego, CA